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Abstract
Object Complement activation has been suggested to play a
role in the development of secondary injuries following
traumatic brain injury (TBI). The present study was
initiated in order to analyze complement activation in
relation to the primary brain injury and to secondary
insults, frequently occurring following TBI.
Methods Twenty patients suffering from severe TBI (Glas-
gow coma score ≤8) were included in the study. The
“membrane attack complex,” C5b9, which is the cytolytic
end product of the complement system was analyzed in
cerebrospinal fluid (CSF). The degree of brain tissue damage
was assessed using the release of S100B and neuron-specific
enolase (NSE) to the CSF and blood. The blood–brain barrier
was assessed using the CSF/serum quotient of albumin (QA).
Results Following impact, initial peaks (0–48 h) of C5b9,
S100B, and NSE with a concomitant loss of integrity of the
blood–brain barrier were observed. Secondary insults at the
intensive care unit were monitored. Severe secondary
insults were paralleled by a more pronounced complement
activation (C5b9 in CSF) as well as increased levels of
S100B (measured in CSF), but not with NSE.
Conclusion This human study indicates that complement
activation in the brain is triggered not only by the impact of
trauma per se but also by the amount of secondary insults
that frequently occur at the scene of accident as well as
during treatment in the neurointensive care unit. Comple-
ment activation and in particular the end product C5b9 may
in turn contribute to additional secondary brain injuries by
its membrane destructive properties.
Keywords Traumatic brain injury . Complement . C5b9 .
S-100B . NSE . Human . Secondary insults
Introduction
Traumatic brain injury (TBI) accounts for the majority of
trauma deaths in Europe today, with an incidence of 235/
100,000 and case mortality rate of approximately 11% [39].
Many of the survivors suffer from various severe sequels. The
effects of TBI are extensive, not only for the victim, but also
for family and friends, and furthermore, the society suffers
huge costs for rehabilitation, care, and productivity loss.
The primary brain injury occurs as a result of the energy
transmitted to the brain tissue at impact. Following impact,
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different secondary insults [25] most often occur, such as
hypoxemia, hypercarbia, seizures, etc. These secondary insults
lead to a disturbed balance between cerebral blood flow
(CBF) and cerebral metabolism [23] with a subsequent risk to
develop ischemia and thus impair outcome [6]. At autopsy,
ischemic injuries have been shown to occur in 80%–90% of
victims that succumb following TBI [14]. The outcome is
further influenced by other biochemical processes initiated by
the trauma. These processes include the release of excitatory
amino acids [30] with a subsequent calcium intoxication of
the neurons [11], formation of reactive oxygen species [12],
activation of neuroinflammation [18, 28] including the
complement system [4, 5, 37], and trauma-induced thrombo-
cyte dysfunction [29]. Furthermore, genetic factors influence
the pathophysiologic events following TBI. Apolipoprotein E
(ApoE) modulates the risk to develop Alzheimer’s disease but
also inflict on the prognosis following TBI [45]. Taken
together, the prognosis for patients suffering from TBI is due
not only to the primary injury but also to the extent of
secondary insults and the biochemical processes that the
patients suffer from as well as the phenotype of the individual.
To counteract these effects of secondary insults, prehospital
trauma teams have been organized, trauma-units launched,
and neurointensive care units (NICUs) established resulting in
improved outcome [33, 38, 44].
The use of markers for tissue damage in the central
nervous system, such as S100B and neuron-specific enolase
(NSE), has been proposed as potentially useful in order to
quantify the extent of the TBI early in the process [16].
The present study aims to analyze complement activation,
the tissue damage markers S100B and NSE, the integrity of
the blood–brain barrier (BBB), and clinical parameters
obtained at the scene of accident (SOA) and at the NICU.
Clinical material and methods
This project was approved by the local ethical committee at
the Karolinska University Hospital in Stockholm (No: 01-
297 and 03-540). Informed consent was obtained from next
of kin. Twenty patients (18 males and 2 female; age, 22–
72 years; median age, 59.5 years) suffering from severe
TBI (Glasgow coma score [GCS], ≤8) admitted to the
neurosurgical intensive care unit at Karolinska University
Hospital in Solna (KS) were included (Table 1). Ten of the
patients arrived from the SOA, while 10 were admitted
from a primary hospital.
Patients presenting bilateral wide nonreacting pupils and
GCS 3 judged by the neurosurgeon on call to be beyond
salvage, or patients unconscious mainly due to drug or
alcohol intoxication, as well as patients presenting terminal
illness or for some other reason judged not to be possible
for follow up were excluded from the study.
Fifteen of the patients were subjected to evacuation of
mass lesions and/or hemicraniectomy. All 20 patients had
an intraventricular catheter inserted for continuous intracra-
nial pressure (ICP) monitoring. Zero-point for ICP, systolic
arterial blood pressure (SAP), and mean arterial blood
pressure (MAP) was the temple. All patients were treated in
30° sitting position. Following surgery, the patients were
treated at the NICU. All patients except three were
suffering from isolated TBI. Patient 6 suffered from an
additional pneumothorax, patient 8 suffered from costal
fractures and a lung contusion, and patient 9 suffered from
a C3 fracture.
Occurrences of secondary insults at the SOA were
obtained from the prehospital trauma team charts. Respira-
tory insufficiency was defined as SpO2 below 85% or notes
in the chart indicating “insufficient breathing,” “cyanosis,”
etc. Insufficient circulation was defined as a SAP <90 mm
Hg. Glasgow coma score (GCS) and pupil reaction were
documented at admission (GCSad), and the best GCS within
24 h following admission (GCSb) was registered (Table 1).
During ventilator treatment, all patients were sedated
using midazolam and/or propofol together with infusion or
intermittent administration of Morfine. Intractable intracrani-
al hypertension was treated using intermittent cerebrospinal
drainage, moderate hyperventilation, and barbiturate coma.
All patients performed at least one initial computed
tomography (CT) and a subsequent follow-up within the
first 24 h posttrauma. CT scans were classified ad modum
Marshall [22] (Table 1).
All patients were monitored online using a computerized
surveillance system, intensive care unit (ICU) pilot (CMA
Microdialysis, Solna, Sweden). The following values
exceeding a duration of 5 min were defined as secondary
insults at the NICU; ICP >20 mm Hg, cerebral perfusion
pressure (CPP) <60 mm Hg, MAP <70 mm Hg or MAP
>110 mm Hg, SAP <90 mm Hg or SAP >160 mm Hg,
saturation (SaO2) <90%, pulse <50 beats/min or >120
beats/min, and temperature >38°C. The insults were graded
as mild, moderate, or severe (Table 2).
Except for standard laboratory test procedures, addi-
tional samples of CSF and blood were obtained at
admission and every morning for analysis of S-100B,
NSE, and albumin. The soluble form of the complement
systems cytolytic terminal membrane attack complex,
C5b9, was analyzed in daily samples of CSF, as a marker
for CNS complement activation. S100B and NSE were
analyzed using commercially available chemiluminomet-
ric immunoassays (Liaison Sangtec 100 and Liaison
Sangtec NSE; DiaSorin, Salugia, Italy). The complement
compound C5b9 was analyzed using enzyme immunoas-
say (Quidel A009, Quidel CA. USA).
The levels in CSF of soluble C5b9 has been evaluated in
healthy controls and found to be ranging between not
Acta Neurochir (2011) 153:90–100 91
T
ab
le
1
P
at
ie
nt
s
P
at
ie
nt
s
S
O
A
S
ta
tu
s
C
T
C
S
F
S
er
um
B
B
B
N
o.
A
ge
(y
)
S
ex
R
es
pi
ra
to
ry
C
ir
cu
la
tio
n
S
ei
zu
re
s
E
tio
lo
gy
E
ne
rg
y
G
C
S
ad
G
C
S
b
P
up
C
T
M
S
10
0B
N
S
E
C
5b
9
S
10
0B
N
S
E
Q
A
G
O
S
1
70
M
−
−
−
F
al
l
L
ow
4
9
0
5
54
27
14
0.
77
14
6
4
2
54
F
−
−
−
R
TA
L
ow
8
8
0
5
31
10
8
0.
9
16
1
4
3
22
M
−
+
−
F
al
l
>
3
m
H
ig
h
7
7
0
5
23
17
21
1.
7
27
7
4
4
67
M
N
K
N
K
N
K
F
al
l
L
ow
7
8
0
5
15
3
58
12
4
0.
39
13
72
3
5
59
M
+
−
(+
)
F
al
l
L
ow
7
9
0
5
50
52
11
0
0.
84
13
59
4
6
31
M
−
−
−
A
ss
au
lt
L
ow
8
8
0
2
61
15
4
54
0.
97
22
16
4
7
60
M
−
−
−
R
TA
L
ow
3
3
0
5
21
4
55
38
0.
93
15
10
1
8
68
M
+
−
+
F
al
l
>
3
m
H
ig
h
7
7
2
2
18
6
28
2
18
6
1.
3
15
92
3
9
24
M
+
−
+
R
TA
H
ig
h
3
4
2
4
1,
05
8
62
0
44
2.
1
26
21
1
10
72
F
−
N
K
−
F
al
l
L
ow
8
14
0
5
57
4
19
6
38
0
1.
4
17
75
4
11
60
M
N
K
−
N
K
F
al
l
L
ow
5
9
1
5
50
21
80
0.
17
17
7
3
12
66
M
−
N
K
−
F
al
l
L
ow
7
10
0
5
22
6
52
29
0.
3
9,
5
36
3
13
65
M
+
−
(+
)
F
al
l
L
ow
3
10
1
5
94
28
15
2
0.
37
9,
9
33
1
14
30
M
−
−
+
F
al
l
L
ow
7
8
0
5
20
7
56
11
3
0.
35
10
13
5
15
50
M
−
−
−
R
TA
H
ig
h
8
8
0
2
12
1
39
25
0.
5
9,
9
7
3
16
64
M
N
K
N
K
+
F
al
l
L
ow
6
6
0
5
64
14
67
0.
48
9,
4
14
1
17
65
M
−
+
−
A
ss
au
lt
L
ow
3
7
0
5
24
13
9
0.
6
13
5
3
18
41
M
+
N
K
−
R
TA
H
ig
h
8
8
0
6
56
6
1,
27
3
N
K
0.
4
12
35
3
19
48
M
−
−
+
F
al
l
L
ow
7
7
1
5
15
0
32
8
16
1
1.
7
17
48
3
20
40
M
−
−
(+
)
F
al
l
>
3
m
H
ig
h
3
10
0
5
19
8
13
8
44
0.
51
13
19
4
SO
A
sc
en
e
of
ac
ci
de
nt
;
V
er
if
ie
d
+
,
su
sp
ec
te
d
(+
),
or
ab
se
nt
(−
)
re
sp
ir
at
or
y,
ci
rc
ul
at
or
y
in
su
ff
ic
ie
nc
y
or
on
go
in
g
se
iz
ur
e;
N
K
no
t
kn
ow
n;
R
TA
ro
ad
tr
af
fi
c
ac
ci
de
nt
;
H
ig
h
hi
gh
im
pa
ct
;
L
ow
lo
w
im
pa
ct
;
G
C
Sa
d
G
la
sg
ow
co
m
a
sc
or
e
at
ad
m
is
si
on
;
G
C
Sb
be
st
G
C
S
re
gi
st
er
ed
w
ith
in
fi
rs
t
24
h;
P
up
P
up
il
re
ac
tio
n
to
lig
ht
;
C
T
M
C
T
pe
rf
or
m
ed
be
fo
re
op
er
at
io
n
sc
or
ed
ad
m
od
um
M
ar
sh
al
l;
C
SF
ce
re
br
os
pi
na
l
fl
ui
d;
B
B
B
bl
oo
d–
br
ai
nb
ar
ri
er
;
Q
A
cs
f-
al
bu
m
in
/s
-a
lb
um
in
ra
tio
;
C
SF
/S
er
um
/B
B
B
,
C
5b
9,
S1
00
B
,
N
SE
,
an
d
Q
A
,
hi
gh
es
t
m
ea
su
re
d
va
lu
es
(0
–4
8
h
po
st
tr
au
m
a)
de
fi
ne
d
as
in
iti
al
pe
ak
va
lu
es
;
G
O
S
G
la
sg
ow
ou
tc
om
e
sc
or
e
3–
12
m
on
th
s
af
te
r
ad
m
is
si
on
tr
au
m
a;
F
fe
m
al
e;
M
m
al
e.
0
=
no
rm
al
;
1
=
un
ila
te
ra
l
no
nr
ea
ct
iv
e;
2
=
bi
la
te
ra
l
no
nr
ea
ct
iv
e
92 Acta Neurochir (2011) 153:90–100
detectable levels up to 12 μg/mL [37]. From seven
orthopedic patients anesthetized using spinal anesthesia, we
change a range from csf-S100B between 0.86 and 2.4 μg/L
(mean ± SD, 1.29±0.55) and csf-NSE 5.2 and 14.0 μg/L
(mean ± SD, 8.10±3.2). Each patient was followed as long
as ventilator treatment and ICP monitoring proceeded.
Traumatic disruption of the BBB leads to a leakage of
plasma proteins from blood to the cerebral parenchyma
[42]. BBB integrity was measured as the ratio of CSF–
albumin (mg/L)/serum–albumin (g/L) (QA) [41]. A ratio
below 7 was regarded as normal [20, 41].
Outcome was assessed using Glasgow outcome scale
(GOS) at discharge, and following 3 months to 1 year after
trauma [31, 40] (Table 1). Disability Rating Scale [32],
Functional Independent Score [7], and Mini-Mental State
Examination [9] were used 3 months to 12 months
posttrauma.
The data were collected online to a computerized patient
surveillance system, ICU pilot (CMA Microdialysis, Stock-
holm, Sweden) and analyzed statistically using the Mann–
Whitney U-test or regression analysis (Statistica for
Windows 8.0; StatSoft, Tulsa, OK). For Mann–Whitney
U-test, p<0.05 was used as significance. For regression
analysis, p<0.05 and R2>0.20 were used as significance.
Results
Primary brain injury
Following impact, initial peaks were found in CSF, defined
as the highest obtained value 0–48 h postinjury, of C5b9
(csf-C5b9), S100B (csf-S100B), NSE (csf-NSE), and QA
(Fig. 1a–d; Table 1) as well as the corresponding serum
levels of S100B (s-S100B) and NSE (s-NSE) were noted.
The highest initial peak values within 48 h after trauma
were csf-S100B 23–1,058 μg/L (median, 136 μg/L), csf-
NSE 10–1,273 μg/L (median, 54 μg/L), and csf-C5b9 8–
380 ng/L (median, 54 ng/L) (Table 1). The highest initial
peak value within 48 h of s-S100B ranged between 0.17
and 2.10 μg/L (median, 0.83 μg/L). The corresponding
level for s-NSE was 9.40–27.00 μg/L (mean, 14.94;
median, 13.50 μg/L).
No correlations were found between the tissue damage
markers or csf-C5b9 versus energy at impact, occurrence
of additional extracranial injuries, GCS at admission or
best GCS within the first 24 h, surgical procedures,
or outcome.
There was a significant positive correlation between
csf-NSE and csf-S100B (R2=0.46, p<0.005; Fig. 2a) as
well as between s-NSE and s-S100B (R2=0.63, p<0.001;
Fig. 2b). There was a significant positive correlation also
between s-S100B and csf-S100B (R2=0.20, p<0.05;
Fig. 2c), which was not found between s-NSE and csf-
NSE (R2=0.02, p=0.55; not shown). Serum levels of
NSE, but not csf-NSE, inversely correlated to age (R2=
0.32, p=0.01; not shown).
Blood–brain barrier
The initial peak values for S100B and NSE were analyzed
versus QA. There were no correlations between either csf-
S100B or s-S100B and disturbed BBB integrity (QA) as well
as between csf-NSE or s-NSE and QA. To analyze the
influence of disturbed BBB integrity on the serum levels of
the tissue damage markers, each csf-S100B was multiplied
with the corresponding QA. There was no correlation between
csf-S100B × QA and s-S100B (R
2=0.16, p=0.08; not
shown), nor between csf-NSE × QA and s-NSE (R
2=0.003,
p=0.82; not shown). There was no correlation between the
initial peak values for csf-C5b9 and csf-S100B or between
csf-C5b9 and csf-NSE, but there was a correlation between
csf-C5b9 and QA (R
2=0.58, p<0.0001; Fig. 2d).
Secondary insults at SOA
Five patients presented insufficient respiration on the SOA
and two patients presented unstable circulation with a SAP
Mild Moderate Severe
Intracranial hypertension ICP (mm Hg) 20–30 30–40 >40
Poor cerebral perfusion CPP (mm Hg) 50–60 40–50 <40
Hypotension MAP (mm Hg) 55–70 40–55 <40
Hypotension SAP (mm Hg) 70–90 50–70 <50
Hypertension MAP (mm Hg) 110–130 130–150 >150
Hypertension SAP (mm Hg) 160–190 190–220 >220
Hypoxia SpO2 (%) 85–90 80–85 <80
Bradycardia bpm 40–50 30–40 <30
Tachycardia bpm 120–135 135–150 >150
Pyrexia °C 38–39 39–40 >40
Table 2 Secondary insults at
the NICU
ICP intracranial pressure; CPP
cerebral perfusion pressure;
MAP mean arterial blood pres-
sure; SAP systolic arterial blood
pressure; SpO2 oxygen satura-
tion; bpm beats per minute
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≤90 mm Hg. Eight patients presented epileptic seizures or
“suspect” seizures (Table 1). None of the patients were
subjected to cardiorespiratory resuscitation at the SOA,
during transport, at the primary hospital, the trauma unit,
or at the NICU. All together, secondary insults at the SOA
were verified in 11 of 20 patients. Increased levels of
C5b9 were found in patients presenting at least one
secondary insults at the scene of trauma (p=0.05;
Fig. 3a). These patients also presented a significant
disturbed BBB integrity (p<0.05; Fig. 3b). The levels of
csf-S100B and csf-NSE were also increased in patients
presenting secondary insults at the SOA, but were not
statistically significant.
When specifying type of secondary insult into “respirato-
ry insult,” “circulatory insult,” or “seizure/suspect seizure,”
we found that “seizures/suspected seizures” at SOA corre-
lated to csf-C5b9 (p<0.05; Fig. 3c) and a trend for disturbed
BBB integrity QA (p=0.062; Fig. 3d). “Respiratory insults”
csf-C5b9 (mean +-SEM)
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Fig. 1 Temporal pattern of the
CSF levels for C5b9 and of the
tissue damage markers S100b
and NSE as well as the temporal
pattern for BBB integrity (QA;
[normal value for QA <7]). a
Mean values (±SEM) of C5b9.
b Blood–brain barrier, QA. c csf-
S100B. d csf-NSE from patients
treated at the NICU due to TBI.
Note the initial peak in C5b9,
initial loss of BBB integrity
(QA), and initial peaks in csf-
S100B and csf-NSE and their
subsequent development during
the ICU stay. Y-bar: ng/L for
C5b9, μg/L for csf-S100B and
csf-NSE. dpi days postinjury
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Fig. 2 a In CSF, there is a
significant correlation between
the peak levels of csf-NSE and
csf-S100B within 48 h after
trauma (R2=0.4605, p<0.005).
b In serum, there is a significant
correlation between the peak
levels of s-NSE and s-S100B
within 48 h after trauma (R2=
0.6261, p<0.001). c The peak
levels of S100B in CSF and
serum correlate (R2=0.2028, p<
0.05). d Loss of BBB integrity
(QA) and the levels in CSF of
the terminal complement com-
plex C5b9 correlate significantly
(R2=0.5802, p<0.0001).
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at the SOA correlated to disturbed BBB integrity, QA (p<
0.05; Fig. 3e).
Pupil reaction
Fifteen patients presented normal pupil reactions to light
stimulation at admission. The remaining 5 patients pre-
sented unilateral or bilateral nonreacting pupils. There was
no significant correlation between S100B, NSE, or QA
between the groups. However, a significant increase in csf-
C5b9 was found in patients presenting nonresponsive
pupils (p<0.05; Fig. 4).
CT classification ad modum Marshall
CT classification ad modum Marshall (CTM; Table 1) was
performed on the first CT scan. When several CT scans
preceded surgery, the CT obtained prior to operation was
used for classification. The majority of patients (14 of 20)
presented CTM grade 5 with hematomas that was surgically
evacuated. One patient presented CTM grade 6. Four
patients (patients 6, 8, 9, and 15) presented diffuse injuries
(3 patients CTM grade 2 and one patient CTM grade 4).
By comparing the group of patients with diffuse injuries
(CTM grades 1–4) versus patients with focal injuries (CTM
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Fig. 3 a There was an increase in the initial peak values for C5b9 in
the 11 patients where at least one secondary insult was verified at the
SOA in comparison with the five patients without secondary insults
(Mann–Whitney U-test, p<0.05). The remaining four patients with
uncertain history of early secondary insults are not included in this
analysis. b A statistically significant increased loss of integrity of the
BBB, assessed by the initial peak values for QA, was found when
comparing the group of 11 patients with at least one secondary insults
at the SOA, compared with the 5 patients without secondary insults
(Mann–Whitney U-test, p<0.05). c The complement complex C5b9 in
CSF was significantly higher among patients presenting seizures or
“suspected” seizures (n=8) compared with patients with no seizures
(n=10) at the SOA (Mann–Whitney U-test, p<0.05). d The patients
suffering from seizures or suspected seizures at the SOA also
presented a trend for impaired BBB integrity compared with patients
without seizures (Mann–Whitney U-test, p=0.062). e Patients pre-
senting respiratory insults (n=5) at the SOA presented more disturbed
BBB integrity (Mann–Whitney U-test, p<0.05) than patients with no
respiratory secondary insults at SOA (n=12). Sec ins secondary
insults; SOA scene of accident. Bar: first to third quartile
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grades 5–6), there were somewhat higher values for S100B
and NSE in CSF in the group presenting diffuse injuries,
but not statistically significant.
Secondary insults at NICU
The total monitored time possible to analyze was 2,520 h.
The levels of the tissue damage markers and the comple-
ment protein C5b9 were analyzed in relation to the
occurrences of secondary insults during the NICU stay
registered by the ICU pilot system. To become registered as
a secondary insult, the value had to be outside normal range
for at least 5 consecutive minutes. The magnitude of these
insults was graded into mild, moderate, and severe
(Table 2).
The monitoring data were divided into 24-h periods. All
24-h periods where CSF was not possible to obtain, due to
dysfunctional ventricular drains or slit ventricles, were
excluded as well as all 24-h periods with insufficient
monitoring data concerning the occurrence of secondary
insults. A total number of twenty-one 24-hour periods were
omitted. Furthermore, patient no 11 (Table 1) was excluded
from this part of the study, as he was not monitored for
more than the first 24 h. Patient 20 (Table 1) was excluded
because of loss of data concerning vital parameters due to a
computer error. The total number of 24-h periods possible
to evaluate was 104. The number of individuals that
completed each 24-h period is shown in Fig. 5a. The
temporal distribution of registered moderate and severe
secondary insults is shown in Fig. 5b. No vital parameters
have been registered to the computer system while patients
have been on operation or transported to the radiological
department for CT or magnetic resonance imaging scans.
As CPP is dependent on ICP and MAP, CPP was
excluded as secondary insult and analyzed separately. All
one hundred four 24-h intervals were analyzed as indepen-
dent parameters using regression analysis.
The most prominent secondary insult was mild intracranial
hypertension (ICP, 20–30 mm Hg) with a total time of 30
027 min, followed by mild pyrexia (temperature, 37–38°C)
25,501 min and mild poor CPP (50–60 mm Hg) for
12,147 min.
Correlations were found between csf-S100B and csf-
NSE (R2=0.3823, p<0.001; Fig. 6a) and between s-S100B
and s-NSE (R2=0.4635, p<0.001; Fig. 6b). The relation
between serum and CSF levels for S100B (R2=0.0269, p=
0.0998; not shown) did not correlate, but for NSE, it did but
with a poor R2-value (R2=0.1377, p<0.001; not shown).
A correlation between csf-C5b9 and disturbed BBB
integrity, QA, was found (R
2=0.5034, p<0.001; Fig. 6c).
Furthermore, similar correlations were found between csf-
S100B and QA (R
2=0.2157, p<0.001; Fig. 6d), csf-S100B
and csf-C5b9 (R2=0.2090, p<0.001; Fig. 6e), but not
between csf-NSE and csf-C5b9.
The 104 periods of 24 h were divided into “group A”: No
moderate or severe secondary insults, “group B”: <1 h of
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Fig. 4 Five of 20 patients presented unilateral or bilateral nonreactive
pupils at admission. Patients presenting unilateral or bilateral
nonreactive pupils showed statistically significant higher peak values
of C5b9 in CSF in comparison with the patients presenting normal
pupil reaction (Mann–Whitney U-test, p<0.05). SOA scene of
accident. Bar: first to third quartile
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moderate and/or severe secondary insults, “group C”: 1–2 h
of moderate and/or severe secondary insults, “group D”: 2–
3 h of moderate and/or severe secondary insults, and “group
E”: >3 h of moderate and/or severe secondary insults. The
data were analyzed using Mann–Whitney U-test. There were
no differences in tissue damage markers between “group A”
and “group B” or “group C.” Between “group A” and
“group D,” a statistically increased level of C5b9 was found
in “group D” (p<0.05; Fig. 7a). Between “group A” and
“group E,” statistically significant increased levels for C5b9
(p<0.01; Fig. 7a), csf-S100B (p<0.01; Fig. 7a), and QA (p<
0.05; Fig. 7b) were found.
No correlation between secondary insults and NSE in
CSF was observed. CPP as a solely secondary insult did not
correspond to tissue damage markers or C5b9.
Outcome
No correlation was found between outcome (GOS, Disabil-
ity Rating Scale, or Functional Independent Score) and
early (0–48 h) or late peak levels (>24 h) of C5b9, S100B,
NSE, or QA. No correlation was found between secondary
insults at the NICU and outcome. Of the four patients that
died following TBI, one presented a huge subdural
hematoma, two presented large contusions, and the fourth
patient suffered from a severe diffuse TBI (CTM grade 4) as
a result of a high-energy impact. This patient presented the
highest value of S100B obtained in serum (2.1 μg/L) as
well as in CSF (1,058 μg/L).
Discussion
The present study demonstrates an increase of csf-C5b9 in
CSF following TBI, paralleled by an increase of the tissue
damage markers S100B and NSE. The finding of increased
csf-C5b9 from patients suffering from TBI is an indirect
evidence for activation of the complement system in line
with previous studies [4, 37].
C5b9 has been shown to accumulate at the surface of
neurons located in the border zone in the immediate vicinity to
contusion injuries [4]. Complement activation has the ability
to play a significant role in the development of secondary
brain injuries mediated by the cytolytic effects of C5b9 [26].
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Fig. 6 a There is a correlation
between the two tissue damage
markers S100B and NSE in CSF
during the NICU stay (R2=
0.3823, p<0.001). b A correla-
tion between S100B and NSE is
also found in serum during the
NICU stay (R2=0.4635, p<
0.001). c The complement com-
plex C5b9 correlates to loss of
BBB integrity during the NICU
stay (R2=0.5034, p<0.001). d
The loss of BBB integrity also
correlates to the levels of S100B
in CSF (R2=0.2157, p<0.001).
e The levels of the tissue dam-
age marker S100B correlate to
the complement complex C5b9
in CSF during the NICU stay
(R2=0.2090, p<0.001).
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The activation of complement has been regarded to be
initiated by impact, but in the present study, the occurrence of
secondary insults at the SOA, as well as at the NICU stay,
seems to intensify the complement activation and, furthermore,
leads to a more pronounced loss of BBB integrity.
A weakness in assessing BBB integrity using QA is that
patients suffering from TBI sometimes exhibit intraventric-
ular hemorrhage. Intraventricular hemorrhage implies albu-
min content in the CSF, not originating from a disintegrated
BBB itself but from injured vessels, a fact that might
disturb the efficacy of QA to assess BBB integrity.
S100B is a protein, which in the CNS is present in
astrocytes, and the increase in CSF following TBI may
reflect a release when these cells degenerate in the primary
lesion area. However, an increased synthesis in hypertro-
phic astrocytes in the glial scar that gradually develops in
the border zone may contribute to the increased levels of
this protein as well. In peripheral tissues, S100B is present
also in other cells, e.g., Schwann cells in peripheral nerves
[35], fat cells, muscle, and marrow in mediastinal blood [2].
Elevated S100B concentrations in serum immediately after
multitrauma have been shown to be difficult to interpret
because of extracerebral contributions [1]. However, S100B
in CSF should mainly and probably exclusively represent
the CNS tissue and more specifically the astrocytes.
NSE is a “neuron specific enzyme,” albeit found in
extracerebral sources such as the erytrocytes. NSE has been
shown to increase significantly with hemolysis [13]. The
increase in CSF found in this study was interpreted as a
result from leaking neurons due to membrane destructions
caused by either primary (mechanical) or secondary (neuro-
inflammatory) mechanisms.
The serum levels of S100B and NSE did not correlate to
the BBB integrity, neither at SOA, nor during the NICU
period. The levels of S100B in CSF and serum correlate,
but the corresponding serum levels of S100B do not
correlate to the product of csf-S100B × QA. Thus, BBB
integrity seems to be of a minor importance when assessing
the extent of the primary brain injury using serum levels of
S100B and NSE.
One would expect that a more profound traumatic impact
would release more S100B and NSE, but when the patients
in this study were grouped into high- versus low-energy
trauma at impact, no differences in initial peaks of S100B or
NSE were detected between the groups. Still, to analyze the
mechanism of impact only from information gained by the
charts from the prehospital trauma teams is an uncertain
method. All patients except three were suffering from
isolated TBI. By excluding these patients and recalculate,
there were still no correlations between QA and serum levels
of S100B or NSE, indicating that extracerebral sources of
the tissue damage markers were not a significant explana-
tion for the mismatch with impaired BBB integrity.
Furthermore, themajority of the patients in the present study
suffered from focal lesions, why conclusions concerning
strictly diffuse brain injuries should be drawn with caution.
In the present study, diffuse injuries on CT at admission
represented by CTM grades 2–4 showed no significant
difference in levels of tissue damage markers compared
with patients presenting more focal lesions (CTM grades 5–
6). In a recent study, serum levels of NSE was found to
correlate significantly with the injury severity score and CT
findings [46]. The serum levels of NSE as well as S100B
also have been shown to significantly correlate with the
volume of contusions [17]. Those findings could not be
verified in our study.
There are no valid methods available to quantify the
degree of tissue damage following diffuse, focal, or
combined TBI. However, a combination of clinical exam-
ination, magnetic resonance imaging, and an increased
knowledge of various tissue markers like S100B, NSE, and
C5b9 and their dynamics following TBI might be useful in
Moderate  and severe secondary insults at NICU (Bar = Q3)
0
20
40
60
80
100
120
140
160
csf-NSE csf-S100B csf-C5b9
Secondary insults at NICU
cs
f-S
10
0B
 
an
d 
NS
E 
(u
g/L
);
cs
f-C
5b
9 
(n
g/L
)
p < 0.01
p < 0.05
p < 0.01
Moderate and severe secondary insults at 
NICU (Bar = Q3)
0
10
20
30
40
50
60
QA
Secondary insults at NICU
Q
A
0 hour (gr A)
0-1 hour (gr B)
1-2 hours (gr C)
2-3 hours (gr D)
>3hours (gr E)
p < 0.05
a b
Fig. 7 a There are increasing levels of S100B and C5b9 in CSF with
increasing incidences of moderate and/or severe secondary insults
during the NICU stay. Statistical significance was achieved for csf-
S100B when moderate and/or severe secondary insults occurred more
than 3-h /24-h period (p<0.05). The complement complex C5b9 was
statistically increased already when moderate and/or severe secondary
insults occurred 2–3 h (p<0.05) and was even stronger when
secondary insults occurred more than 3 h (p<0.01). b The integrity
of BBB was significantly impaired when moderate and/or severe
secondary insults occurred more than 3 h at the NICU stay (p<0.05).
Bar: third quartile
98 Acta Neurochir (2011) 153:90–100
the future in order to estimate the long-term prognosis for
the neurotraumatized patient.
Secondary insults (Table 2) have been argued to cause
ischemic lesions in the contusion border zones or globally in
the brain, eventually contributing to the development of
secondary brain injuries, and thus worsen the outcome [19].
In this study, we found more pronounced complement
activation (csf-C5b9) as well as increased levels of csf-
S100B in patients where more secondary insults were detected
during the ICU period. These findings suggest that comple-
ment activation is further triggered by such secondary insults,
which in turn may induce secondary neuronal injuries by the
effect of C5b9. One would expect NSE to mimic the S100B
pattern; however, the statistical data in this study failed to
confirm this, perhaps due to a too low number of observations.
The correlation between initial peaks of csf-C5b9 and QA
indicates that neuroinflammatory mechanisms are involved
in the loss of integrity of the BBB that occurs following TBI.
These findings are congruent with a previous study [37].
Cytokines have been shown to have a potential impact on
BBB integrity by causing an increasing permeability in
cultured endothelial cells [8, 24]. Tumor necrosis factor
(TNF) α contributed to loss of BBB integrity following TBI
[27] and has been shown to have an influence on the
complement system [36]. Stimulation by TNF-α of rat
astrocytes resulted in elevation of C3 mRNA [34] and
treatment of adult human astrocytes in vitro with TNF-α
increased mRNA and protein of complement C3 [3]. A
recent animal study has shown that microglial activation and
increased synthesis of the complement component C1q
preceded loss of BBB integrity in rats [21].
Based on such findings, one may argue that anti-
inflammatory therapy should have effect on brain edema
related to the loss of BBB integrity, which, however, is a
question that remains obscure and need to be further addressed.
Even though steroids are known to reduce the inflammatory
response after TBI [43], a randomized placebo-controlled trial
of intravenous corticosteroid in adults with head injury (the
CRASH study) showed an increased mortality in humans
treated with steroids [10].
Patients suffering from long-term neuropsychological
impairment have been shown to present significantly higher
serum concentrations of NSE as well as a more prolonged
release of NSE than patients presenting no neuropsycho-
logical impairment [15]. In the present study, no correlation
between tissue damage markers, BBB integrity, and
outcome was found.
Conclusion
The complement system does not only become activated by
the trauma per se but also appears to be further triggered by
secondary insults at the SOA as well as at the NICU stay.
The study underscores the importance of meticulous
monitoring of TBI patients in the ICU in order to rapidly
recognize, identify, and treat secondary insults aiming at
minimizing secondary brain damages. The relation between
secondary insults and neuroinflammation has to be further
explored aiming to find directed treatment strategies. The
serum levels of the tissue damage marker S100B do not
seem to be overwhelmingly influenced by the loss of BBB
integrity, indicating that S100B may reflect the true cellular
damage following TBI.
Acknowledgements The study was approved by the local ethical
committee (01-297; 03-540). The staff at NICU, especially Pia
Svensson, R.N., and Birgitta Ohlgren, R.N., are gratefully acknowl-
edged for their everlasting enthusiasm and help concerning the present
project. Mrs. Rumjana Dijlai-Merzoug is greatly acknowledged for
excellent laboratory technical assistance. Magnus Backheden and
Margaretha Krook are acknowledged for their help and guidance
concerning the statistical analysis. This study was funded by the
Stockholm county and the Swedish Medical Research Council.
Open Access This article is distributed under the terms of the
Creative Commons Attribution Noncommercial License which per-
mits any noncommercial use, distribution, and reproduction in any
medium, provided the original author(s) and source are credited.
Conflicts of interest None.
References
1. Anderson RE, Hansson LO, Nilsson O, Dijlai-Merzoug R,
Settergren G (2001) High serum S100B levels for trauma patients
without head injuries. Neurosurgery 48:1255–1258
2. Anderson RE, Hansson LO, Nilsson O, Liska J, Settergren G, Vaage J
(2001) Increase in serum S100A1-B and S100BB during cardiac surgery
arises from extracerebral sources. Ann Thorac Surg 71:1512–1517
3. Barnum SR, Jones JL, Benveniste EN (1993) Interleukin-1 and
tumor necrosis factor-mediated regulation of C3 gene expression
in human astroglioma cells. Glia 7:225–236
4. Bellander BM, Singhrao SK, Ohlsson M, Mattsson P, Svensson M
(2001) Complement activation in the human brain after traumatic
head injury. J Neurotrauma 18:1295–1311
5. Bellander BM, von Holst H, Fredman P, Svensson M (1996)
Activation of the complement cascade and increase of clusterin in
the brain following a cortical contusion in the adult rat. J
Neurosurg 85:468–475
6. Chesnut RM, Marshall LF, Klauber MR, Blunt BA, Baldwin N,
Eisenberg HM, Jane JA, Marmarou A, Foulkes MA (1993) The
role of secondary brain injury in determining outcome from severe
head injury. J Trauma 34:216–222
7. Corrigan JD, Smith-Knapp K, Granger CV (1997) Validity of the
functional independence measure for persons with traumatic brain
injury. Arch Phys Med Rehabil 78:828–834
8. de Vries HE, Blom-Roosemalen MC, van Oosten M, de Boer AG,
van Berkel TJ, Breimer DD, Kuiper J (1996) The influence of
cytokines on the integrity of the blood–brain barrier in vitro. J
Neuroimmunol 64:37–43
9. Dick JP, Guiloff RJ, Stewart A, Blackstock J, Bielawska C, Paul
EA, Marsden CD (1984) Mini-mental state examination in
neurological patients. J Neurol Neurosurg Psychiatry 47:496–499
Acta Neurochir (2011) 153:90–100 99
10. Edwards P, Arango M, Balica L, Cottingham R, El-Sayed H,
Farrell B, Fernandes J, Gogichaisvili T, Golden N, Hartzenberg B,
Husain M, Ulloa MI, Jerbi Z, Khamis H, Komolafe E, Laloë V,
Lomas G, Ludwig S, Mazairac G, Muñoz Sanchéz Mde L, Nasi L,
Olldashi F, Plunkett P, Roberts I, Sandercock P, Shakur H, Soler
C, Stocker R, Svoboda P, Trenkler S, Venkataramana NK,
Wasserberg J, Yates D, Yutthakasemsunt S, CRASH Trial
Collaborators (2005) Final results of MRC CRASH, a randomised
placebo-controlled trial of intravenous corticosteroid in adults
with head injury-outcomes at 6 months. Lancet 365:1957–1959
11. Faden AI, Demediuk P, Panter SS, Vink R (1989) The role of
excitatory amino acids and NMDA receptors in traumatic brain
injury. Science 244:798–800
12. Freeman BA, Crapo JD (1982) Biology of disease: free radicals
and tissue injury. Lab Invest 47:412–426
13. Gao F, Harris DN, Sapsed-Byrne S, Sharp S (1997) Neurone-specific
enolase and Sangtec 100 assays during cardiac surgery: part III—
dose haemolysis affect their accuracy? Perfusion 12:171–177
14. Graham DI, Adams JH, Gennarelli TA (1993) Pathology of brain
damage in head injury. In: Cooper PR (ed) Head injury. Williams
& Wilkins, Baltimore, pp 91–113
15. Herrmann M, Curio N, Jost S, Grubich C, Ebert AD, Fork ML,
Synowitz H (2001) Release of biochemical markers of damage to
neuronal and glial brain tissue is associated with short and long
term neuropsychological outcome after traumatic brain injury. J
Neurol Neurosurg Psychiatry 70:95–100
16. Herrmann M, Curio N, Jost S, Wunderlich MT, Synowitz H,
Wallesch CW (1999) Protein S-100B and neuron specific enolase
as early neurobiochemical markers of the severity of traumatic
brain injury. Restor Neurol Neurosci 14:109–114
17. Herrmann M, Jost S, Kutz S, Ebert AD, Kratz T, Wunderlich MT,
Synowitz H (2000) Temporal profile of release of neurobiochem-
ical markers of brain damage after traumatic brain injury is
associated with intracranial pathology as demonstrated in cranial
computerized tomography. J Neurotrauma 17:113–122
18. Holmin S, Mathiesen T, Sheteye J, Biberfeld P (1995) Intracere-
bral inflammatory response to experimental brain contusion. Acta
Neurochir 132:110–119
19. Jones PA, Andrews PJD, Midgley S, Anderson SI, Piper IR, Tocher
JL, Housley AM, Corrie JA, Slattery J, Dearden NM, Miller JD
(1994) Measuring the burden of secondary insults in head-injured
patients during intensive care. J Neurosurg Anesthesiol 6:4–14
20. Link H, Tibbling G (1977) Principles of albumin and IgG analyses in
neurological disorders. II. Relation of the concentration of the proteins
in serum and cerebrospinal fluid. Scand J Clin Lab Invest 37:391–396
21. Lynch NJ, Willis CL, Nolan CC, Roscher S, Fowler MJ, Weihe E,
Ray DE, Schwaeble WJ (2004) Microglial activation and
increased synthesis of complement component C1q precedes
blood–brain barrier dysfunction in rats. Mol Immunol 40:709–716
22. Marshall LF, Marshall SB, Klauber MR, Van Berkum CM,
Eisenberg H, Jane JA, Luerssen TG, Marmarou A, Foulkes MA
(1992) The diagnosis of head injury requires a classification based
on computed axial tomography. J Neurotrauma 9:S287–S292
23. Martin NA, Patwardhan RV, Alexander MJ, Africk CZ, Lee JH,
Shalmon E, Hovda DA, Becker DP (1997) Characterization of
cerebral hemodynamic phases following severe head trauma:
hypoperfusion, hyperemia, and vasospasm. J Neurosurg 87:9–19
24. Maruo N, Morita I, Shirao M, Murota S (1992) IL-6 increases
endothelial permeability in vitro. Endocrinology 131:710–714
25. Miller JD, Piper IR, Jones PA (1995) Pathophysiology of head
injury. In: Narayan RK, Wilberger JE Jr, Povlishock JT (eds)
Neurotrauma. McGraw-Hill, New York, pp 61–69
26. Morgan BP (1999) Regulation of the complement membrane
attack pathway. Crit Rev Immunol 19:173–198
27. Morganti-Kossman MC, Lenzlinger PM, Hans V, Stahel P, Csuka
E, Ammann E, Stocker R, Trentz O, Kossmann T (1997)
Production of cytokines following brain injury: beneficial and
deleterious for the damaged tissue. Mol Psychiatry 2:133–136
28. Morganti-Kossmann MC, Rancan M, Stahel PF, Kossmann T
(2002) Inflammatory response in acute traumatic brain injury: a
double-edged sword. Curr Opin Crit Care 8:101–105
29. Nekludov M, Bellander BM, Blombäck M, Wallen HN (2007)
Platelet dysfunction in patients with severe traumatic brain injury.
J Neurotrauma 11:1699–1706
30. Olney JW (1986) Inciting excitotoxic cytocide among central
neurons. Adv Exp Med Biol 203:631–645
31. Pettigrew LE, Wilson JT, Teasdale GM (2003) Reliability of ratings
on the Glasgow Outcome Scales from in-person and telephone
structured interviews. J Head Trauma Rehabil 18:252–258
32. Rappaport M, Hall KM, Hopkins K, Belleza T, Cope DN (1982)
Disability Rating Scale for severe head trauma: coma to
community. Arch Phys Med Rehabil 63:118–123
33. Rudehill A, Bellander BM, Weitzberg E, Bredbacka S, Backheden
M, Gordon E (2002) Outcome of traumatic brain injuries in 1, 508
patients: impact of prehospital care. J Neurotrauma 19:855–868
34. Rus HG, Kim LM, Niculescu FI, Shin ML (1992) Induction of C3
expression in astrocytes is regulated by cytokines and Newcastle
disease virus. J Immunol 148:928–933
35. Sandelin M, Zabihi S, Liu L, Wicher G, Kozlova EN (2004)
Metastasis-associated S100A4 (Mts1) protein is expressed in
subpopulations of sensory and autonomic neurons and in
Schwann cells of the adult rat. J Comp Neurol 473:233–243
36. Stahel PF, Kariya K, Shohami E, Barnum SR, Eugster H, Trentz
O, Kossmann T, Morganti-Kossmann MC (2000) Intracerebral
complement C5a receptor (CD88) expression is regulated by TNF
and lymphotoxin-alpha following closed head injury in mice. J
Neuroimmunol 109:164–172
37. Stahel PF, Morganti-Kossmann C, Perez D, Redaelli C, Gloor B,
Trentz O, Kossmann T (2001) Intrathecal levels of complement-
derived soluble membrane attack complex (sC5b-9) correlate with
blood–brain barrier dysfunction in patients with traumatic brain
injury. J Neurotrauma 18:773–781
38. Suarez JI, Zaidat OO, Suri MF, Feen ES, Lynch G, Hickman J,
Georgiadis A, Selman WR (2004) Length of stay and mortality in
neurocritically ill patients: impact of a specialized neurocritical
care team. Crit Care Med 32:2311–2317
39. Tagliaferri F, Compagnone C, Korsic M, Servadei F, Kraus J
(2006) A systematic review of brain injury in Europe. Acta
Neurochir (Wien) 148:255–268
40. Teasdale GM, Pettigrew LE, Wilson JT, Murray G, Jennett B
(1998) Analyzing outcome of treatment of severe head injury: a
review and update on advancing the use of the Glasgow Outcome
Scale. J Neurotrauma 15:587–597
41. Tibbling G, Link H, Öhman S (1977) Principles of albumin and
IgG analyses in neurological disorders. I. Establishment of
reference values. Scand J Clin Lab Invest 37:385–390
42. Todd NV, Graham DI (1990) Blood–brain barrier damage in
traumatic brain contusions. Acta Neurochir Suppl 51:296–299
43. VanLandingham JW, Cekic M, Cutler S, Hoffman SW, Stein DG
(2007) Neurosteroids reduce inflammation after TBI through
CD55 induction. Neurosci Lett 25:94–98
44. Varelas PN, Conti MM, Spanaki MV, Potts E, Bradford D,
Sunstrom C, Fedder W, Hacein Bey L, Jaradeh S, Gennarelli TA
(2004) The impact of a neurointensivist-led team on a semiclosed
neurosciences intensive care unit. Crit Care Med 32:2191–2198
45. Waters RJ, Nicoll JA (2005) Genetic influences on outcome
following acute neurological insults. Curr Opin Crit Care 11:105–
110
46. Vos PE, Lamers KJ, Hendriks JC, van Haaren M, Beems T,
Zimmerman C, van Geel W, de Reus H, Biert J, Verbeek MM
(2004) Glial and neuronal proteins in serum predict outcome after
severe traumatic brain injury. Neurology 62:1303–1310
100 Acta Neurochir (2011) 153:90–100
